Document Detail

Comparison of long-term efficacy of the paclitaxel-eluting stent versus the bare-metal stent for treatment of unprotected left main coronary artery disease.
MedLine Citation:
PMID:  19121435     Owner:  NLM     Status:  MEDLINE    
The use of paclitaxel-eluting stents (PES) for the treatment of unprotected left main coronary artery (LMCA) disease is controversial. Between January 2003 and December 2006, a total of 287 patients undergoing percutaneous coronary intervention for LMCA lesions were consecutively registered. Of those patients, 178 received PES and 109 received bare-metal stents (BMS). Estimated perioperative mortality rates were 7.3% and 6.8% for the BMS and PES groups, respectively (p=0.51). PES recipients had distal left main bifurcation lesions more frequently compared with BMS recipients (72 vs 42%, p<0.01). At an average follow-up of 35 months, the rates of major adverse cardiac events (4.5 vs 23.9%, adjusted odds ratio [OR] 0.23, 95% confidence interval [CI] 0.09 to 0.58, p<0.001) and target-lesion revascularization (2.2 vs 13.8%, adjusted OR 0.26, 95% CI 0.08 to 0.83, p<0.001) were significantly lower in the PES group than in the BMS group. Overall thrombotic event rates were 1.1% and 4.6% in the PES and BMS groups, respectively (p=0.08). Angiographic follow-up was performed in 61% and 59% of PES and BMS recipients, respectively. The angiographic restenosis rate was significantly lower in the PES group as compared with the BMS group (3.7 vs 23.4%, p<0.001). In conclusion, PES implantation provides a safe, effective therapy for unprotected LMCA disease and decreases the risk of major adverse cardiac events compared with BMS at a mean follow-up of 35 months.
Yaling Han; Shouli Wang; Quanmin Jing; Yi Li; Haiwei Liu; Yingyan Ma; Zulu Wang; Dongmei Wang; Bo Luan; Geng Wang; Tao Chen
Related Documents :
2099035 - New mechanical devices for treatment of coronary artery disease.
24576075 - Death due to coronary artery insufficiency following blunt trauma to the chest.
12975255 - Elevated whole-blood tissue factor procoagulant activity as a marker of restenosis afte...
11163525 - Source displacement during the cardiac cycle in coronary endovascular brachytherapy.
9932205 - Radiofrequency catheter ablation for postinfarct ventricular tachycardia.
318355 - Immunological, electrophoretic and kinetic properties of cardiac myosins from various s...
Publication Detail:
Type:  Comparative Study; Journal Article     Date:  2008-10-30
Journal Detail:
Title:  The American journal of cardiology     Volume:  103     ISSN:  1879-1913     ISO Abbreviation:  Am. J. Cardiol.     Publication Date:  2009 Jan 
Date Detail:
Created Date:  2009-01-05     Completed Date:  2009-02-10     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0207277     Medline TA:  Am J Cardiol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  194-8     Citation Subset:  AIM; IM    
Department of Cardiology, Shenyang Northern Hospital, Shenyang, 110016, China.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
China / epidemiology
Coronary Angiography
Coronary Artery Disease / mortality,  radiography,  therapy*
Drug-Eluting Stents*
Middle Aged
Paclitaxel / administration & dosage*
Risk Factors
Treatment Outcome
Tubulin Modulators / administration & dosage*
Reg. No./Substance:
0/Tubulin Modulators; 33069-62-4/Paclitaxel

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Comparison of drug-eluting stents and bare-metal stents for the treatment of unprotected left main c...
Next Document:  Paclitaxel-eluting stent long-term outcomes in percutaneous saphenous vein graft interventions (PELO...